Article

Meet The Team

The pathologist is only one member of a patient's care team; cancer treatment and care involve many people with various knowledge and skills.

The pathologist is only one member of a patient’s care team; cancer treatment and care involve many people with various knowledge and skills. The makeup of the team will determine which specialties are best for treating the patient’s type of cancer. Patients should remember that they are at the center of their team, and they have the final voice in making decisions and choices about what happens to them.

Professionals patients may encounter include:

> Medical and radiation oncologists, radiologists, pathologists and surgeons;

> Oncology nurses, nurse practitioners and physician assistants; and

> Social workers, oncology clinical pharmacists, dietitians, occupational and physical therapists, clergy, psychologists and psychiatrists.

Each doctor is supported by a specialized team—staff members who also play a major role in the patient’s care.

Patients should try to understand the role of each person on the team (or teams) so that they can take full advantage of the skills and personal attention available to them.

[Learn more in "Knowing Your Healthcare Team"]

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Daniel Jernazian, who beat cancer twice, credits his sports mindset for survival and calls it winning his ‘life World Championship’.
Patients in rural or underserved areas may have worse outcomes, highlighting the need for early support to address care access barriers.
Image of man with text.
Image of doctor with text.
Dr. Emre Yekedüz discusses how ASCO 2025 highlights precision medicine, biomarkers and the gut microbiome as keys to advancing kidney cancer care.
Dr. Breelyn Wilky stresses the importance of expert guidance and second opinions for patients with GIST, as treatment options continue to evolve rapidly.
Mark Daniels, 83, credits CAR T-cell therapy and compassionate care for helping him overcome lymphoma and endure the isolating treatment toll.
An early study of BGB-16673 for hard-to-treat leukemia found that side effects were manageable with no new safety concerns.
Image of woman with text.
Image of goy, and text.
Related Content